GB Sciences, Inc. CEO Craig Ellins in High Demand as Medical Marijuana Industry Expert
July 31 2014 - 11:00AM
GrowBLOX Sciences, Inc. (OTCQB:GBLX) a medical marijuana research
and development company, announced that CEO Craig Ellins is in high
demand by top tier publications, reporters, and journalists as an
expert in the medical marijuana industry. Recently, several highly
respected media outlets have been contacting GrowBLOX Sciences,
Inc. in hopes of landing an interview with CEO Craig Ellins to
discuss a variety of different topics regarding the medical
marijuana industry. Some of these topics include state legislation
updates, license application processes, challenges faced by medical
marijuana companies, efficacy standards for medical marijuana, and
how to best capitalize on the rapidly growing medical marijuana
industry to name a few.
Mr. Ellins stated, "We are all very pleased to have caught the
attention of so many highly respected media outlets and to be
recognized as an expert in the medical marijuana industry. This
interest is a testament to the quality of our science, technology,
management team and our ability to continue executing our business
plan."
GrowBLOX Sciences, Inc. and CEO Craig Ellins were the focal
point of an article published by www.MainStreet.com titled Cannabis
Dispensary in Nevada Secures Banking Account. Read the entire
article here:
http://www.mainstreet.com/article/small-business/cannabis-dispensary-nevada-secures-banking-account?page=1.
Craig Ellins was also recently quoted in an article by the
International Business Times titled Industrial Hemp Research and
Production on the Rise After New Legislation. Read the entire
article here:
http://www.ibtimes.com/industrial-hemp-research-production-rise-after-new-legislation-1629176.
Mr. Ellins has conducted several interviews being labeled as an
industry expert in the past couple weeks which will lead to
additional articles, quotes, and high quality media placements. Mr.
Ellins continued, "We hope the increased media attention will not
only help educate people on the exciting things happening with
GrowBLOX Sciences, Inc., but increase awareness and understanding
by the medical marijuana community as to what it truly means to
produce a safe, consistent, and effective medicine for
patients."
The Company plans to update shareholders and the investment
community as several of the interviews are expected to be published
within the next one to two weeks.
About GrowBLOX Sciences, Inc.
GrowBLOX Sciences, Inc., is a research and biotechnical company
that has developed proprietary indoor growing chambers specifically
designed for medical cannabis cultivation. The GrowBLOX chamber
allows for completely controlled growing conditions, ensuring the
manufacture of a consistent, toxin-free, natural and
medicinal-grade product. The Company believes that the
advantages of a controlled environment over traditional outdoor or
greenhouse growing, will empower the public, nutraceutical and
pharmaceutical industries to embrace cannabis as an effective
treatment for a myriad of serious medical
conditions. http://www.gbsciences.com
Forward-Looking Statements
Except for historical information contained herein, the
statements in this release are forward-looking and made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are inherently
unreliable and actual results may differ materially. Examples
of forward-looking statements in this news release include
statements regarding the payment of dividends, marketing and
distribution plans, development activities and anticipated
operating results. Factors which could cause actual results
to differ materially from these forward-looking statements include
such factors as the Company's ability to accomplish its business
initiatives, significant fluctuations in marketing expenses and
ability to achieve and expand significant levels of revenues, or
recognize net income, from the sale of its products and services,
as well as the introduction of competing products, or management's
ability to attract and maintain qualified personnel necessary for
the development and commercialization of its planned products, and
other information that may be detailed from time to time in the
Company's filings with the United States Securities and Exchange
Commission. The Company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
CONTACT: Jonathan Barkman
Riverview Capital Enterprises
+1-866-845-0105
GB Sciences (PK) (USOTC:GBLX)
Historical Stock Chart
From Aug 2024 to Sep 2024
GB Sciences (PK) (USOTC:GBLX)
Historical Stock Chart
From Sep 2023 to Sep 2024